Tag Archive for: biotech

Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

/in

RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part by MRC grant Poolbeg will act as the lead business partner alongside Johnson & Johnson and other partners 8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that […]

Read more

Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer

/in

Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape Brings over 15 years of global oncology and hematology leadership, advancing over 10 radioligands across the development spectrum, from preclinical to Phase III   Oslo, Norway and Cambridge, Massachusetts — 3 December 2025 — […]

Read more

Sector updates in November

/in

Investment firms Sofinnova Partners successfully closes its latest flagship fund, Sofinnova Capital XI, with €650 million to back a new generation of pioneering biopharmaceutical and medical technology companies addressing urgent unmet clinical needs Medicxi successfully closes its sixth fund, Medicxi V, with €500 million dedicated to building and backing innovative biotechnology companies with clear product […]

Read more

Weekly roundup: Huge fundraisings, patents approved, award winners and more. Next up Genesis 2025!

/in

What an incredible few days at Jefferies & London Life Science Week! 🎉 A huge thank you to Jefferies, the BioIndustry Association (BIA), MedCity, and London & Partners for hosting this goliath event. It gets bigger, better and more impactful every year, and we’re proud to be part of it. We are glad so many […]

Read more

Poolbeg Pharma plc – POLB 001 European Patent granted

/in

Further strengthens Poolbeg’s global intellectual property portfolio 20 November 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read more…

Read more